Biolase, Inc. (NASDAQ:BIOL) is scheduled to issue its quarterly earnings data after the market closes on Monday, November 6th. Analysts expect the company to announce earnings of ($0.04) per share for the quarter.

Biolase (NASDAQ:BIOL) last released its quarterly earnings results on Monday, August 7th. The medical technology company reported ($0.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.04). Biolase had a negative return on equity of 64.44% and a negative net margin of 31.64%. The firm had revenue of $12.61 million for the quarter. On average, analysts expect Biolase to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Biolase, Inc. (NASDAQ:BIOL) opened at 0.674 on Monday. The firm’s 50-day moving average price is $0.62 and its 200-day moving average price is $0.88. The firm’s market cap is $51.21 million. Biolase, Inc. has a 52-week low of $0.48 and a 52-week high of $1.90.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at

Separately, ValuEngine downgraded Biolase from a “hold” rating to a “sell” rating in a report on Monday, July 24th.

Biolase Company Profile

BIOLASE, Inc (BIOLASE) is a medical device company that develops, manufactures, markets and sells laser systems in dentistry and medicine. The Company markets, sells, and distributes dental imaging equipment, including cone beam digital x-rays and computer-aided design (CAD)/computer-aided manufacturing (CAM) intra-oral scanners, in-office, chair-side milling machines and three-dimensional (3-D) printers.

Earnings History for Biolase (NASDAQ:BIOL)

Receive News & Ratings for Biolase Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biolase Inc. and related companies with's FREE daily email newsletter.